Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Martin Gore et al.|The Lancet|2008Cited by 642
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialAlexander M.M. Eggermont, Danielle Líénard, Stefan Suciu et al.|The Lancet|2005Cited by 314
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III MelanomaAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|Journal of Clinical Oncology|2012Cited by 281
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M.M. Eggermont, Alessandro Testori, Piotr Rutkowski et al.|European Journal of Cancer|2020Cited by 14